Qi Lu is a Senior Director of Analytical Development at Merida Biosciences, bringing over 15 years of experience in the biopharmaceutical industry. They have successfully led analytical method development for two long-acting hemophilia drugs, Alprolix® and Eloctate®. As a proficient analytical lead, Qi has collaborated with cross-functional teams to craft analytical control strategies that support key milestones in drug development. Previously, they held roles at Bioverativ, Invivyd, and Sanofi, among others. Qi is currently pursuing a Master of Science and a PhD in Analytical Chemistry at Wuhan University and Southern Illinois University, Carbondale, respectively.
This person is not in any teams
This person is not in any offices